Global Gastrointestinal Stromal Tumor (GIST) Drug Market Research Report 2023

Publication ID:

PB503237511

Publication Date:

March 22, 2023

Pages:

108

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Highlights
The global Gastrointestinal Stromal Tumor (GIST) Drug market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
North American market for Gastrointestinal Stromal Tumor (GIST) Drug is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Gastrointestinal Stromal Tumor (GIST) Drug is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global manufacturers of Gastrointestinal Stromal Tumor (GIST) Drug include Ariad Pharmaceuticals, Inc., Arog Pharmaceuticals, Inc., Array BioPharma Inc., Astex Pharmaceuticals, Inc., Blueprint Medicines Corporation, Boston Biomedical, Inc., Calithera Biosciences, Inc., Chipscreen Biosciences Ltd and Deciphera Pharmaceuticals, LLC, etc. in 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Gastrointestinal Stromal Tumor (GIST) Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Gastrointestinal Stromal Tumor (GIST) Drug.
The Gastrointestinal Stromal Tumor (GIST) Drug market size, estimations, and forecasts are provided in terms of sales volume (K Pcs) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Gastrointestinal Stromal Tumor (GIST) Drug market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Gastrointestinal Stromal Tumor (GIST) Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.
By Company
Ariad Pharmaceuticals, Inc.
Arog Pharmaceuticals, Inc.
Array BioPharma Inc.
Astex Pharmaceuticals, Inc.
Blueprint Medicines Corporation
Boston Biomedical, Inc.
Calithera Biosciences, Inc.
Chipscreen Biosciences Ltd
Deciphera Pharmaceuticals, LLC
F. Hoffmann-La Roche Ltd.
Horizon Pharma Plc
Immunicum AB
Jiangsu Hengrui Medicine Co., Ltd.
Kolltan Pharmaceuticals, Inc.
Natco Pharma Limited
Nerviano Medical Sciences S.r.l.
Novartis AG
Omeros Corporation
Segment by Type
Amcasertib
Anagrelide hydrochloride CR
APG-1351
Binimetinib
Others
Segment by Application
Clinic
Hospital
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Gastrointestinal Stromal Tumor (GIST) Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Gastrointestinal Stromal Tumor (GIST) Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Gastrointestinal Stromal Tumor (GIST) Drug Market Overview
1.1 Product Overview and Scope of Gastrointestinal Stromal Tumor (GIST) Drug
1.2 Gastrointestinal Stromal Tumor (GIST) Drug Segment by Type
1.2.1 Global Gastrointestinal Stromal Tumor (GIST) Drug Market Value Comparison by Type (2023-2029)
1.2.2 Amcasertib
1.2.3 Anagrelide hydrochloride CR
1.2.4 APG-1351
1.2.5 Binimetinib
1.2.6 Others
1.3 Gastrointestinal Stromal Tumor (GIST) Drug Segment by Application
1.3.1 Global Gastrointestinal Stromal Tumor (GIST) Drug Market Value by Application: (2023-2029)
1.3.2 Clinic
1.3.3 Hospital
1.3.4 Others
1.4 Global Gastrointestinal Stromal Tumor (GIST) Drug Market Size Estimates and Forecasts
1.4.1 Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue 2018-2029
1.4.2 Global Gastrointestinal Stromal Tumor (GIST) Drug Sales 2018-2029
1.4.3 Global Gastrointestinal Stromal Tumor (GIST) Drug Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Gastrointestinal Stromal Tumor (GIST) Drug Market Competition by Manufacturers
2.1 Global Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Manufacturers (2018-2023)
2.2 Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Gastrointestinal Stromal Tumor (GIST) Drug Average Price by Manufacturers (2018-2023)
2.4 Global Gastrointestinal Stromal Tumor (GIST) Drug Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Gastrointestinal Stromal Tumor (GIST) Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Gastrointestinal Stromal Tumor (GIST) Drug, Product Type & Application
2.7 Gastrointestinal Stromal Tumor (GIST) Drug Market Competitive Situation and Trends
2.7.1 Gastrointestinal Stromal Tumor (GIST) Drug Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Gastrointestinal Stromal Tumor (GIST) Drug Players Market Share by Revenue
2.7.3 Global Gastrointestinal Stromal Tumor (GIST) Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Gastrointestinal Stromal Tumor (GIST) Drug Retrospective Market Scenario by Region
3.1 Global Gastrointestinal Stromal Tumor (GIST) Drug Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Gastrointestinal Stromal Tumor (GIST) Drug Global Gastrointestinal Stromal Tumor (GIST) Drug Sales by Region: 2018-2029
3.2.1 Global Gastrointestinal Stromal Tumor (GIST) Drug Sales by Region: 2018-2023
3.2.2 Global Gastrointestinal Stromal Tumor (GIST) Drug Sales by Region: 2024-2029
3.3 Global Gastrointestinal Stromal Tumor (GIST) Drug Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Region: 2018-2029
3.3.1 Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Region: 2018-2023
3.3.2 Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Region: 2024-2029
3.4 North America Gastrointestinal Stromal Tumor (GIST) Drug Market Facts & Figures by Country
3.4.1 North America Gastrointestinal Stromal Tumor (GIST) Drug Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Gastrointestinal Stromal Tumor (GIST) Drug Sales by Country (2018-2029)
3.4.3 North America Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Country (2018-2029)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Gastrointestinal Stromal Tumor (GIST) Drug Market Facts & Figures by Country
3.5.1 Europe Gastrointestinal Stromal Tumor (GIST) Drug Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Gastrointestinal Stromal Tumor (GIST) Drug Sales by Country (2018-2029)
3.5.3 Europe Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Gastrointestinal Stromal Tumor (GIST) Drug Market Facts & Figures by Country
3.6.1 Asia Pacific Gastrointestinal Stromal Tumor (GIST) Drug Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Gastrointestinal Stromal Tumor (GIST) Drug Sales by Country (2018-2029)
3.6.3 Asia Pacific Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Gastrointestinal Stromal Tumor (GIST) Drug Market Facts & Figures by Country
3.7.1 Latin America Gastrointestinal Stromal Tumor (GIST) Drug Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Gastrointestinal Stromal Tumor (GIST) Drug Sales by Country (2018-2029)
3.7.3 Latin America Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Gastrointestinal Stromal Tumor (GIST) Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Gastrointestinal Stromal Tumor (GIST) Drug Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Gastrointestinal Stromal Tumor (GIST) Drug Sales by Country (2018-2029)
3.8.3 Middle East and Africa Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Gastrointestinal Stromal Tumor (GIST) Drug Sales by Type (2018-2029)
4.1.1 Global Gastrointestinal Stromal Tumor (GIST) Drug Sales by Type (2018-2023)
4.1.2 Global Gastrointestinal Stromal Tumor (GIST) Drug Sales by Type (2024-2029)
4.1.3 Global Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Type (2018-2029)
4.2 Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Type (2018-2029)
4.2.1 Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Type (2018-2023)
4.2.2 Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Type (2024-2029)
4.2.3 Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue Market Share by Type (2018-2029)
4.3 Global Gastrointestinal Stromal Tumor (GIST) Drug Price by Type (2018-2029)
5 Segment by Application
5.1 Global Gastrointestinal Stromal Tumor (GIST) Drug Sales by Application (2018-2029)
5.1.1 Global Gastrointestinal Stromal Tumor (GIST) Drug Sales by Application (2018-2023)
5.1.2 Global Gastrointestinal Stromal Tumor (GIST) Drug Sales by Application (2024-2029)
5.1.3 Global Gastrointestinal Stromal Tumor (GIST) Drug Sales Market Share by Application (2018-2029)
5.2 Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Application (2018-2029)
5.2.1 Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Application (2018-2023)
5.2.2 Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Application (2024-2029)
5.2.3 Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue Market Share by Application (2018-2029)
5.3 Global Gastrointestinal Stromal Tumor (GIST) Drug Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Ariad Pharmaceuticals, Inc.
6.1.1 Ariad Pharmaceuticals, Inc. Corporation Information
6.1.2 Ariad Pharmaceuticals, Inc. Description and Business Overview
6.1.3 Ariad Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Ariad Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolio
6.1.5 Ariad Pharmaceuticals, Inc. Recent Developments/Updates
6.2 Arog Pharmaceuticals, Inc.
6.2.1 Arog Pharmaceuticals, Inc. Corporation Information
6.2.2 Arog Pharmaceuticals, Inc. Description and Business Overview
6.2.3 Arog Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Arog Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolio
6.2.5 Arog Pharmaceuticals, Inc. Recent Developments/Updates
6.3 Array BioPharma Inc.
6.3.1 Array BioPharma Inc. Corporation Information
6.3.2 Array BioPharma Inc. Description and Business Overview
6.3.3 Array BioPharma Inc. Gastrointestinal Stromal Tumor (GIST) Drug Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Array BioPharma Inc. Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolio
6.3.5 Array BioPharma Inc. Recent Developments/Updates
6.4 Astex Pharmaceuticals, Inc.
6.4.1 Astex Pharmaceuticals, Inc. Corporation Information
6.4.2 Astex Pharmaceuticals, Inc. Description and Business Overview
6.4.3 Astex Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Astex Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolio
6.4.5 Astex Pharmaceuticals, Inc. Recent Developments/Updates
6.5 Blueprint Medicines Corporation
6.5.1 Blueprint Medicines Corporation Corporation Information
6.5.2 Blueprint Medicines Corporation Description and Business Overview
6.5.3 Blueprint Medicines Corporation Gastrointestinal Stromal Tumor (GIST) Drug Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Blueprint Medicines Corporation Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolio
6.5.5 Blueprint Medicines Corporation Recent Developments/Updates
6.6 Boston Biomedical, Inc.
6.6.1 Boston Biomedical, Inc. Corporation Information
6.6.2 Boston Biomedical, Inc. Description and Business Overview
6.6.3 Boston Biomedical, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Boston Biomedical, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolio
6.6.5 Boston Biomedical, Inc. Recent Developments/Updates
6.7 Calithera Biosciences, Inc.
6.6.1 Calithera Biosciences, Inc. Corporation Information
6.6.2 Calithera Biosciences, Inc. Description and Business Overview
6.6.3 Calithera Biosciences, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Calithera Biosciences, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolio
6.7.5 Calithera Biosciences, Inc. Recent Developments/Updates
6.8 Chipscreen Biosciences Ltd
6.8.1 Chipscreen Biosciences Ltd Corporation Information
6.8.2 Chipscreen Biosciences Ltd Description and Business Overview
6.8.3 Chipscreen Biosciences Ltd Gastrointestinal Stromal Tumor (GIST) Drug Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Chipscreen Biosciences Ltd Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolio
6.8.5 Chipscreen Biosciences Ltd Recent Developments/Updates
6.9 Deciphera Pharmaceuticals, LLC
6.9.1 Deciphera Pharmaceuticals, LLC Corporation Information
6.9.2 Deciphera Pharmaceuticals, LLC Description and Business Overview
6.9.3 Deciphera Pharmaceuticals, LLC Gastrointestinal Stromal Tumor (GIST) Drug Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Deciphera Pharmaceuticals, LLC Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolio
6.9.5 Deciphera Pharmaceuticals, LLC Recent Developments/Updates
6.10 F. Hoffmann-La Roche Ltd.
6.10.1 F. Hoffmann-La Roche Ltd. Corporation Information
6.10.2 F. Hoffmann-La Roche Ltd. Description and Business Overview
6.10.3 F. Hoffmann-La Roche Ltd. Gastrointestinal Stromal Tumor (GIST) Drug Sales, Revenue and Gross Margin (2018-2023)
6.10.4 F. Hoffmann-La Roche Ltd. Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolio
6.10.5 F. Hoffmann-La Roche Ltd. Recent Developments/Updates
6.11 Horizon Pharma Plc
6.11.1 Horizon Pharma Plc Corporation Information
6.11.2 Horizon Pharma Plc Gastrointestinal Stromal Tumor (GIST) Drug Description and Business Overview
6.11.3 Horizon Pharma Plc Gastrointestinal Stromal Tumor (GIST) Drug Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Horizon Pharma Plc Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolio
6.11.5 Horizon Pharma Plc Recent Developments/Updates
6.12 Immunicum AB
6.12.1 Immunicum AB Corporation Information
6.12.2 Immunicum AB Gastrointestinal Stromal Tumor (GIST) Drug Description and Business Overview
6.12.3 Immunicum AB Gastrointestinal Stromal Tumor (GIST) Drug Sales, Revenue and Gross Margin (2018-2023)
6.12.4 Immunicum AB Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolio
6.12.5 Immunicum AB Recent Developments/Updates
6.13 Jiangsu Hengrui Medicine Co., Ltd.
6.13.1 Jiangsu Hengrui Medicine Co., Ltd. Corporation Information
6.13.2 Jiangsu Hengrui Medicine Co., Ltd. Gastrointestinal Stromal Tumor (GIST) Drug Description and Business Overview
6.13.3 Jiangsu Hengrui Medicine Co., Ltd. Gastrointestinal Stromal Tumor (GIST) Drug Sales, Revenue and Gross Margin (2018-2023)
6.13.4 Jiangsu Hengrui Medicine Co., Ltd. Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolio
6.13.5 Jiangsu Hengrui Medicine Co., Ltd. Recent Developments/Updates
6.14 Kolltan Pharmaceuticals, Inc.
6.14.1 Kolltan Pharmaceuticals, Inc. Corporation Information
6.14.2 Kolltan Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Description and Business Overview
6.14.3 Kolltan Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Sales, Revenue and Gross Margin (2018-2023)
6.14.4 Kolltan Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolio
6.14.5 Kolltan Pharmaceuticals, Inc. Recent Developments/Updates
6.15 Natco Pharma Limited
6.15.1 Natco Pharma Limited Corporation Information
6.15.2 Natco Pharma Limited Gastrointestinal Stromal Tumor (GIST) Drug Description and Business Overview
6.15.3 Natco Pharma Limited Gastrointestinal Stromal Tumor (GIST) Drug Sales, Revenue and Gross Margin (2018-2023)
6.15.4 Natco Pharma Limited Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolio
6.15.5 Natco Pharma Limited Recent Developments/Updates
6.16 Nerviano Medical Sciences S.r.l.
6.16.1 Nerviano Medical Sciences S.r.l. Corporation Information
6.16.2 Nerviano Medical Sciences S.r.l. Gastrointestinal Stromal Tumor (GIST) Drug Description and Business Overview
6.16.3 Nerviano Medical Sciences S.r.l. Gastrointestinal Stromal Tumor (GIST) Drug Sales, Revenue and Gross Margin (2018-2023)
6.16.4 Nerviano Medical Sciences S.r.l. Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolio
6.16.5 Nerviano Medical Sciences S.r.l. Recent Developments/Updates
6.17 Novartis AG
6.17.1 Novartis AG Corporation Information
6.17.2 Novartis AG Gastrointestinal Stromal Tumor (GIST) Drug Description and Business Overview
6.17.3 Novartis AG Gastrointestinal Stromal Tumor (GIST) Drug Sales, Revenue and Gross Margin (2018-2023)
6.17.4 Novartis AG Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolio
6.17.5 Novartis AG Recent Developments/Updates
6.18 Omeros Corporation
6.18.1 Omeros Corporation Corporation Information
6.18.2 Omeros Corporation Gastrointestinal Stromal Tumor (GIST) Drug Description and Business Overview
6.18.3 Omeros Corporation Gastrointestinal Stromal Tumor (GIST) Drug Sales, Revenue and Gross Margin (2018-2023)
6.18.4 Omeros Corporation Gastrointestinal Stromal Tumor (GIST) Drug Product Portfolio
6.18.5 Omeros Corporation Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Gastrointestinal Stromal Tumor (GIST) Drug Industry Chain Analysis
7.2 Gastrointestinal Stromal Tumor (GIST) Drug Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Gastrointestinal Stromal Tumor (GIST) Drug Production Mode & Process
7.4 Gastrointestinal Stromal Tumor (GIST) Drug Sales and Marketing
7.4.1 Gastrointestinal Stromal Tumor (GIST) Drug Sales Channels
7.4.2 Gastrointestinal Stromal Tumor (GIST) Drug Distributors
7.5 Gastrointestinal Stromal Tumor (GIST) Drug Customers
8 Gastrointestinal Stromal Tumor (GIST) Drug Market Dynamics
8.1 Gastrointestinal Stromal Tumor (GIST) Drug Industry Trends
8.2 Gastrointestinal Stromal Tumor (GIST) Drug Market Drivers
8.3 Gastrointestinal Stromal Tumor (GIST) Drug Market Challenges
8.4 Gastrointestinal Stromal Tumor (GIST) Drug Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

Ariad Pharmaceuticals, Inc.
Arog Pharmaceuticals, Inc.
Array BioPharma Inc.
Astex Pharmaceuticals, Inc.
Blueprint Medicines Corporation
Boston Biomedical, Inc.
Calithera Biosciences, Inc.
Chipscreen Biosciences Ltd
Deciphera Pharmaceuticals, LLC
F. Hoffmann-La Roche Ltd.
Horizon Pharma Plc
Immunicum AB
Jiangsu Hengrui Medicine Co., Ltd.
Kolltan Pharmaceuticals, Inc.
Natco Pharma Limited
Nerviano Medical Sciences S.r.l.
Novartis AG
Omeros Corporation

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂